We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 64 for:    lyme

Study on Early Lyme Neuroborreliosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00910533
Recruitment Status : Recruiting
First Posted : June 1, 2009
Last Update Posted : May 5, 2017
Sponsor:
Information provided by (Responsible Party):

May 28, 2009
June 1, 2009
May 5, 2017
June 2009
June 2018   (Final data collection date for primary outcome measure)
Objective sequelae and post-treatment subjective symptoms in patients treated with ceftriaxone for early Lyme neuroborreliosis [ Time Frame: 1 year follow-up ]
Same as current
Complete list of historical versions of study NCT00910533 on ClinicalTrials.gov Archive Site
Comparison of subjective symptoms between patients treated with ceftriaxone for early Lyme neuroborreliosis and control subjects without a history of Lyme borreliosis [ Time Frame: 1 year follow-up ]
Same as current
Not Provided
Not Provided
 
Study on Early Lyme Neuroborreliosis
Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis
The purpose of this study is to determine clinical course and the sequelae of early Lyme neuroborreliosis after treatment with ceftriaxone.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Nervous System Lyme Borreliosis
Drug: ceftriaxone
ceftriaxone 2 g od i.v. for 14 days
  • Active Comparator: Early Lyme neuroborreliosis patients
    Intervention: Drug: ceftriaxone
  • No Intervention: control subjects
    Control subjects without a history of Lyme borreliosis.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
June 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • erythema migrans within 4 months before neurologic involvement and pleocytosis in patients >15 years old

Exclusion Criteria:

  • pregnancy
  • lactation
  • history of adverse reaction to a beta-lactam antibiotic
Sexes Eligible for Study: All
15 Years and older   (Child, Adult, Senior)
Yes
Contact: Dasa Stupica, MD +38615222110 cerar.dasa@gmail.com
Contact: Franc Strle, MD +38615222110 franc.strle@kclj.si
Slovenia
 
 
NCT00910533
LNB-0509
No
Not Provided
Not Provided
Franc Strle, University Medical Centre Ljubljana
University Medical Centre Ljubljana
Not Provided
Study Chair: Franc Strle, MD UMC Ljubljana
University Medical Centre Ljubljana
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP